MA-ONPROCESS-TECHNOLOGY
30.9.2021 13:02:11 CEST | Business Wire | Press release
OnProcess Technology, Inc. , a global pioneer powering the world’s circular service supply chains, announced today the general availability of its new cloud-based technology platform, OnProcess Agora™ along with Agora Recover™, an asset recovery solution that delivers new levels of digital customer experience. The OnProcess Agora platform, which hosts a suite of applications, communications and business intelligence tools underpinned by a proprietary data model, helps improve the management, efficiency and orchestration at every stage of the service-parts supply chain. The solution automates key after-sales processes and equips customers with a digital-first approach that results in greater financial, sustainability and customer service outcomes.
Today’s after-sale supply chain continues to be incredibly manual, siloed and complex. This makes orchestrating a circular supply chain – where manufacturers and sellers order, consume, return and refurbish used parts to cut down on costs, reduce waste and improve service – nearly impossible. OnProcess Agora™ overcomes this challenge by integrating the entire service supply chain into a single platform and automatically capturing and blending parts data, customer data and OnProcess proprietary data across the post-sale service lifecycle.
“The after-sale service supply chain has a direct and substantial impact on customer service, sustainability outcomes and the bottom line. Unfortunately, the typical service supply chain today is a web of disconnected, manual processes managed by siloed departments and systems,” said Oliver Lemanski, CEO of OnProcess. “That’s why we designed Agora, which gives our customers complete control and visibility across the service supply chain, and uniquely combines parts management data with data that focuses on the customer experience. The platform is a key enabler of our company’s vision to power the world’s circular service supply chains and puts sustainability and customer lifetime value at the heart of the everything-as-a-service economy.”
OnProcess’ AI-driven digital solution for asset recovery, Agora Recover™ , is the first application to be released on the OnProcess Agora™ platform. With sophisticated reporting capabilities, self-service portals and cloud-based integrations into almost any application or data source, Agora Recover supports the circular service supply chain by giving customers a holistic view of the parts recovery cycle. The resulting visibility and intelligence reduce unnecessary transportation costs and promotes sustainability by intelligently redirecting recovered parts according to value, demand and reusability.
“Agora Recover makes it easier to recover the inventory that matters most and provides new digital services for a more frictionless customer experience,” added Lemanski. “By providing real-time information to the right people, when and where they need it, helps teams recover parts faster, make better decisions, optimize operations, improve warranty recovery, reduce costs and emissions, and significantly improve customer satisfaction.”
To learn more about OnProcess Agora™ or Agora Recover™, or to request a demonstration, visit www.onprocess.com .
About OnProcess Technology, Inc.
OnProcess supplies technology and services that powers the world’s circular service supply chains. Providing managed services and digital transformation expertise that streamlines processes, maximizes customer lifetime value, and improves ‘circular’ sustainability goals, OnProcess is a trusted advisor to many of the world’s leading computer, networking, med-tech, wireless, telecommunications, and IT companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005199/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom